2021 年半年度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2021 年半年度报告 1 / 144 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风 ...

Financial Performance - The company's operating revenue for 2020 was RMB 4,205,109,097.87, representing a 12.66% increase compared to RMB 3,732,718,882.94 in 2019[26]. - The net profit attributable to shareholders of the listed company was RMB 227,876,516.65, an increase of 87.94% from RMB 121,251,309.89 in 2019[26]. - The basic earnings per share increased to CNY 0.26, representing an 85.71% increase from CNY 0.14 in the previous year[28]. - The diluted earnings per share also rose to CNY 0.25, an increase of 78.57% compared to CNY 0.14 in the previous year[28]. - The weighted average return on net assets was 7.31%, an increase of 3.23 percentage points from 4.08% in the previous year[28]. - The total assets at the end of the reporting period were CNY 7,272,824,836.06, a 2.59% increase from CNY 7,089,268,238.84 at the end of the previous year[28]. - The net assets attributable to shareholders increased by 6.38% to CNY 3,213,975,896.55 from CNY 3,021,159,128.79 in the previous year[28]. - The company reported a total revenue of CNY 1,139,500,133.00 in the fourth quarter, showing a sequential increase from CNY 1,066,634,009.00 in the third quarter[29]. - The net cash flow from operating activities was CNY 234,552,377.73, down 35.18% from CNY 361,866,734.40 in the previous year[28]. - The company achieved an annual revenue of CNY 4.205 billion, representing a year-on-year growth of 12.66%[62]. - The net profit attributable to shareholders reached CNY 228 million, with a significant year-on-year increase of 87.94%[62]. Dividends and Profit Distribution - The board proposed a cash dividend of RMB 0.55 per 10 shares, totaling RMB 48,412,635.43 to be distributed to shareholders[7]. - The net profit attributable to ordinary shareholders for the fiscal year 2020 was 227,876,516.65 RMB, representing a profit distribution ratio of 21.25%[173]. - The company implemented a cash dividend plan for the fiscal year 2020, distributing a cash dividend of 0.55 RMB per 10 shares, totaling 48,412,635.43 RMB (including tax) to shareholders[173]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[11]. - The company has outlined various risks and corresponding countermeasures in its operational analysis section[11]. - The company faced risks related to raw material procurement due to factors such as increased environmental investment and rising labor costs, which could lead to a surge in procurement costs or shortages[167]. - The company has established a comprehensive quality assurance system in compliance with national GMP certification, ensuring controlled production processes to mitigate product quality risks[166]. - The company has a dynamic management system for suppliers and implements annual supply agreements to ensure supply security and control procurement costs[167]. - The company faces risks related to industry policy changes, R&D challenges, and environmental regulations, which could impact future operations[160][161][162]. Research and Development - The company’s R&D expenses increased by 36.77% to CNY 192.63 million, reflecting a commitment to innovation[63]. - The total R&D investment reached ¥241,683,364.30, representing 5.75% of operating income, exceeding the industry average[80]. - The company is focusing on increasing R&D investment, with development expenditures rising to ¥179,052,332.02, accounting for 2.46% of total assets, up 21.93% from the previous period[87]. - The company is actively expanding its product pipeline with a focus on both innovative and generic drugs[124]. - The company is committed to maintaining a competitive R&D investment level compared to industry peers, with a higher R&D investment ratio than some competitors[129]. - Major R&D projects included the registration of Acarbose tablets with an investment of 8.79 million RMB, and the consistency evaluation of Entecavir dispersible tablets with an investment of 5.46 million RMB, showing significant year-on-year changes of 162.76% and 117.22% respectively[131]. Market and Sales Performance - The sales of non-antibiotic products increased by more than 10% year-on-year[50]. - The sales volume of major veterinary drug formulations grew by over 50% year-on-year due to active adjustments in marketing strategies[50]. - Domestic revenue accounted for CNY 3.419 billion, with a year-on-year increase of 17.89%[68]. - The company’s products ranked among the top ten in the national market for 57 specifications, and it was ranked 46th in the "Top 100 Comprehensive Strength of China's Chemical Pharmaceutical Industry" in 2020[49]. - The company is focusing on expanding its market share in both domestic and international markets through innovative marketing strategies and product differentiation[50]. Operational Efficiency - Cost reduction efforts led to a total cost decrease of approximately CNY 113 million, with a comparable cost reduction rate exceeding 4%[58]. - The asset-liability ratio decreased to 53.81%, down by 1.45 percentage points year-on-year[57]. - The company implemented automation and intelligent construction, reducing personnel by over 20%[58]. - The company is focusing on reducing operational costs through information technology upgrades and standardizing data processes[154]. Compliance and Governance - The company has committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[6]. - The audit report issued by the accounting firm was a standard unqualified opinion[6]. - The company has not faced any violations in decision-making procedures regarding external guarantees[9]. - The company reported no major litigation or arbitration matters during the fiscal year[179]. - The company has not disclosed any significant related party transactions for the fiscal year[181]. - The company has not faced any risks of suspension or termination of listing during the reporting period[177]. Strategic Initiatives - The company plans to adapt its operational strategies and product structure in response to national pharmaceutical policies, aiming to maintain and enhance market share in specific segments[102]. - The company intends to shift its product structure from a single focus on antibiotics to a dual focus on antibiotics and innovative drugs[106]. - The company aims to improve product quality and cost-effectiveness while expanding new sales channels and enhancing logistics services[102]. - The company plans to accelerate the industrialization of new products and aims to double the revenue from calcium acetate granules[153]. - The company intends to complete multiple international product registrations within the year to enhance product quality assurance and international competitiveness[153].

2021 年第一季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2021 年第一季度报告 1 / 18 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 18 2021 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | --- | --- | --- | --- | |----------------|----------------|----------------------------|--------------| | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | 颜骏廷 | 董事 | 因公出差，未能亲自参加会议 | 彭 欣 | | 黄正明 | 独立董事 | 因公出差，未能亲自参加会议 | 孙宗彬 | ...

Financial Performance - Operating income for the first nine months was CNY 3,065,608,964.86, representing a year-on-year increase of 12.23%[17] - Net profit attributable to shareholders of the listed company reached CNY 230,209,742.13, up 126.49% year-on-year[17] - Basic earnings per share increased by 116.67% to CNY 0.26[17] - The weighted average return on net assets rose by 3.92 percentage points to 7.34%[17] - The company reported a total profit of ¥10,575,625.32 for Q3 2020, down from ¥25,492,601.20 in Q3 2019, a decline of 58.5%[52] - The net profit for Q3 2020 was -¥50,095,389.26, compared to -¥8,773,041.88 in Q3 2019, indicating a significant decline in profitability[64] - The total comprehensive income attributable to the parent company for Q3 2020 was ¥1,797,855.01, compared to ¥19,936,092.69 in Q3 2019, showing a decrease of about 90.0%[61] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,010,934,318.92, a decrease of 1.10% compared to the end of the previous year[17] - Total liabilities decreased to ¥3,638,997,692.06 from ¥3,917,627,675.83, a decrease of approximately 7.1%[39] - Current liabilities decreased to ¥2,899,727,904.26 from ¥3,201,220,573.52, a reduction of about 9.4%[37] - The company’s total assets reached ¥5,846,787,231.79, up from ¥5,758,273,851.13 year-over-year[44] - Total liabilities were approximately $3.01 billion, with non-current liabilities accounting for about $520 million[86] - The company reported a long-term equity investment of approximately $55.84 million, indicating strategic investments in other entities[78] Cash Flow - Net cash flow from operating activities for the first nine months was CNY 80,989,879.15, an increase of 105.55% compared to the same period last year[17] - The cash flow from operating activities for the first three quarters of 2020 was ¥2,455,563,873.80, down from ¥3,220,785,625.12 in the same period of 2019, a decline of approximately 23.7%[66] - Cash inflow from financing activities reached 2,045,502,640.00, significantly higher than 1,155,252,241.63 in the previous period, showing strong borrowing activity[69] - The net cash flow from financing activities was 190,570,600.02, an increase from 132,739,726.13, suggesting effective capital management[71] - The company experienced a net increase in cash and cash equivalents of -27,576,604.94, compared to -7,001,381.25 in the previous period, highlighting cash flow challenges[71] Shareholder Information - Net assets attributable to shareholders of the listed company increased by 6.48% to CNY 3,216,861,067.05[17] - The total number of shareholders at the end of the reporting period was 161,966[21] - The largest shareholder, Hualu Holdings Group Co., Ltd., held 21.12% of the shares[21] Investments and Expenditures - Research and development expenses in Q3 2020 amounted to ¥49,289,820.96, compared to ¥35,242,474.95 in Q3 2019, indicating a 39.9% increase[49] - The company is focusing on enhancing its R&D capabilities to drive future growth, as indicated by the increased R&D spending[61] - The company has ongoing construction projects valued at approximately $660.34 million, reflecting investment in future growth[78] Accounting Policies - The implementation of the new revenue recognition standard did not have a significant impact on the financial statements, with adjustments made only for contracts not completed by January 1, 2020[90] - Under the new leasing standard, the company recognized right-of-use assets and lease liabilities, with long-term payables adjusted to approximately $460.64 million[92] - The company has adopted new accounting policies effective January 1, 2020, for both revenue recognition and leasing, ensuring compliance with updated standards[90]

2020 年第三季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2020 年第三季度报告正文 1 / 6 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|------------------------------------|-------------------------------| | | 本报告期末 | 上年度末 | ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2020—041 山东鲁抗医药股份有限公司 关于参加山东辖区上市公司2020年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的沟通交流，做好投资者关系管理工作，山东鲁 抗医药股份有限公司（以下简称"公司"） 将参加由山东证监局、山东上市公司 协会与深圳市全景网络有限公司联合举办的"山东辖区上市公司 2020 年度投资 者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可以登录"全景 • 路演天下"网站（http://rs.p5w.net）参与本次活动。活动时间为 2020 年 9 月 29 日（星期二）15:00 至 16:55。 届时公司财务总监李利先生、董事会秘书田立新先生、证券事务代表包强明 先生将通过网络在线交流形式与投资者就公司治理、经营状况等投资者关注的问 题进行沟通，欢迎广大投资者积极参与。 特此公告。 山东鲁抗医药股份有限公司董事会 二〇二〇年 ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,998,974,955.67, representing a 7.87% increase compared to CNY 1,853,115,369.55 in the same period last year[22]. - Net profit attributable to shareholders of the listed company reached CNY 228,411,887.12, a significant increase of 179.55% from CNY 81,708,391.92 in the previous year[22]. - Basic earnings per share for the reporting period was CNY 0.2595, up 179.63% from CNY 0.0928 in the same period last year[24]. - The company's total assets as of the end of the reporting period were CNY 7,157,521,643.48, a slight increase of 0.96% from CNY 7,089,268,238.84 at the end of the previous year[24]. - The weighted average return on net assets increased to 7.29%, up by 4.54 percentage points from 2.75% in the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 3,157,388.37, down 95.36% from CNY 67,987,696.47 in the previous year[22]. - The company's net assets attributable to shareholders reached CNY 3,251,855,640.90, an increase of 7.64% from CNY 3,021,159,128.79 at the end of the previous year[24]. - The diluted earnings per share was CNY 0.2571, reflecting a 177.05% increase from CNY 0.0928 in the same period last year[24]. - The company achieved a net profit attributable to shareholders of 228 million yuan, an increase of 147 million yuan, representing a growth of 179.55% year-on-year[41]. - The company reported a total revenue of 1.999 billion yuan for the first half of 2020, a year-on-year increase of 7.87%[50]. Cash Flow and Investments - The net cash flow from operating activities was CNY 3,631,147.69, a decrease of 96.02% compared to CNY 91,140,543.68 in the same period last year[22]. - The company reported a significant increase in asset disposal income of CNY 208 million, attributed to land compensation agreements[70]. - The total amount of long-term borrowings increased by 358.88% to approximately CNY 448.31 million, reflecting a strategy to leverage debt for growth[73]. - The company secured a low-interest loan of 200 million yuan from the government to supplement working capital and reduce costs[51]. - The company reported a net cash outflow from operating activities of ¥55,068,469.55, contrasting with a net inflow of ¥6,583,597.41 in the same period last year[169]. - The total cash flow from investment activities was negative at -¥62,449,557.87, compared to -¥45,392,206.31 in the previous year, indicating a worsening investment cash flow situation[169]. Research and Development - The company has 17 generic drug projects under research and development, with 5 varieties of active pharmaceutical ingredients undergoing process changes[55]. - The company has integrated R&D resources to form a dedicated research institute, enhancing its new product development capabilities[35]. - Research and development expenses rose by 24.53% to approximately CNY 82.08 million, indicating a focus on innovation[64]. - The company obtained 14 patent authorizations, including 3 invention patents, during the reporting period[55]. - Research and development expenses for the first half of 2020 were ¥82,078,005.73, compared to ¥65,911,671.45 in the same period last year, an increase of 24.5%[152]. Market and Industry Position - The pharmaceutical manufacturing industry saw a cumulative value-added growth of 1.8% in the first half of 2020, with total revenue of ¥12,390.4 billion, remaining flat year-on-year[36]. - The company is recognized as a national high-tech enterprise and has a leading market share in core products such as penicillin and semi-synthetic antibiotics[39]. - The company is actively participating in provincial drug centralized procurement, adapting to new pricing and bidding strategies[34]. - The company’s sales model includes channel distribution, terminal delivery, and academic promotion, ensuring extensive market coverage[33]. - The company plans to continue focusing on market expansion and new product development to drive future growth[161]. Environmental Management - The company has established a comprehensive environmental management system and passed ISO14001 certification, enhancing its core competitive advantage in environmental protection[48]. - The company has implemented strict environmental protection measures, adhering to laws such as the Environmental Protection Law and the Water Pollution Prevention Law, with a focus on monitoring and managing pollutants[108]. - The company has established a wastewater treatment facility with a capacity of 80 tons per day, ensuring compliance with discharge standards[109]. - The company has introduced advanced technologies for VOCs treatment, significantly improving the effectiveness of pollution control measures[108]. - All subsidiaries have achieved compliance in pollutant discharge, with no environmental pollution incidents reported in the first half of 2020[118]. Risks and Challenges - The company faces risks related to industry policy changes, which may lead to significant fluctuations in net profit compared to the previous year due to intensified regulatory measures in the pharmaceutical industry[78]. - Environmental and safety production risks are heightened due to stricter regulations and potential equipment failures, despite the company's ongoing commitment to environmental protection[81]. - The company acknowledges R&D risks, including high investment and low success rates, which may lead to mismatches between R&D input and revenue[82]. - The macroeconomic environment, particularly the impact of the COVID-19 pandemic, poses risks to the pharmaceutical industry, affecting operational conditions and growth[83]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 182,299[124]. - The largest shareholder, Hualu Holdings Group Co., Ltd., held 185,896,620 shares, representing 21.12% of the total shares[124]. - The new controlling shareholder is Hualu Holdings Group Co., Ltd., with the change effective from March 10, 2020[130]. - The company did not propose any profit distribution or capital reserve increase for the first half of 2020[88]. Financial Position - Total current assets increased to ¥2,724,486,428.52 as of June 30, 2020, up from ¥2,585,118,402.03 at the end of 2019, representing a growth of approximately 5.4%[136]. - Total liabilities decreased to ¥3,752,174,203.65 from ¥3,917,627,675.83, a reduction of about 4.2%[141]. - The company's total equity attributable to shareholders increased to ¥3,251,855,640.90 from ¥3,021,159,128.79, marking a growth of approximately 7.6%[141]. - The company’s long-term borrowings increased to ¥448,314,236.08 from ¥97,697,364.05, indicating a significant rise of approximately 358.5%[141].

Financial Performance - The company reported a net profit attributable to shareholders of 6.04 million RMB, a decrease of 87.50% compared to the previous year, which was a reduction of 42.26 million RMB [15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -4.55 million RMB, a decrease of 111.33% year-on-year [15]. - The company's net profit for Q1 2020 was CNY 7,492,362.99, a significant decrease from CNY 50,732,617.70 in Q1 2019, representing a decline of approximately 85.2% [49]. - The net profit for Q1 2020 was ¥65,534,794.43, down from ¥72,888,930.29 in Q1 2019, indicating a decrease of 10.1% [44]. - The total profit for Q1 2020 was CNY 10,367,468.76, down from CNY 56,003,388.98 in Q1 2019, reflecting a decrease of approximately 81.5% [49]. - Basic and diluted earnings per share were both 0.01 RMB, down 85.71% from the previous year [12]. - The company's basic and diluted earnings per share for Q1 2020 were both CNY 0.01, down from CNY 0.07 in Q1 2019, a decrease of 85.7% [49]. Revenue and Costs - The operating revenue for the first quarter was 960.05 million RMB, representing a year-on-year increase of 2.45% [12]. - Total operating revenue for Q1 2020 was ¥960,049,128.01, an increase of 2.0% compared to ¥937,091,064.09 in Q1 2019 [44]. - Total operating costs for Q1 2020 were ¥954,981,063.65, up from ¥887,076,717.88 in Q1 2019, reflecting a significant increase of 7.6% [44]. - The company's operating costs for Q1 2020 were CNY 335,182,257.27, reduced from CNY 394,098,557.23 in Q1 2019, indicating a decrease of about 14.9% [49]. Cash Flow - The net cash flow from operating activities was -79.19 million RMB, a significant decline of 311.80% compared to the previous year [12]. - The net cash flow from operating activities was -79,185,003.48 RMB, a decrease from 37,385,987.66 RMB in the previous period, indicating a significant decline in operational performance [55]. - Cash inflow from operating activities was 1,086,955,111.43 RMB, slightly down from 1,139,129,941.74 RMB, suggesting a decline in revenue generation [55]. - Cash outflow for investing activities was 124,881,008.01 RMB, compared to 227,059,401.36 RMB previously, showing a reduction in investment expenditures [55]. - The total cash and cash equivalents at the end of the period amounted to 624,975,826.82 RMB, down from 676,886,638.18 RMB, indicating a decrease in liquidity [57]. Assets and Liabilities - Total assets at the end of the reporting period were 7.33 billion RMB, an increase of 3.39% from the end of the previous year [12]. - Total current assets amounted to ¥2,741,721,680.00, an increase from ¥2,585,118,402.03 [29]. - Total liabilities increased to ¥4,150,289,239.99 from ¥3,917,627,675.83 [35]. - Total equity reached ¥3,179,132,926.00, up from ¥3,171,640,563.01 [35]. - Current liabilities totaled ¥3,201,220,573.52, including short-term borrowings of ¥1,057,000,000.00 and accounts payable of ¥715,306,434.00 [65]. - Total liabilities reached ¥3,917,627,675.83, with non-current liabilities at ¥716,407,102.31, including long-term borrowings of ¥97,697,364.05 [65]. Shareholder Information - The company’s major shareholder, Hualu Holdings Group, holds 21.12% of the shares, making it the direct controlling shareholder [23]. - Shareholders' equity totaled ¥3,171,640,563.01, with total equity attributable to the parent company at ¥3,021,159,128.79 [67]. Operational Challenges - The company faced significant impacts on its product procurement, production, and sales due to the COVID-19 pandemic, leading to reduced gross profit [15]. - The market price of veterinary medicine products declined due to the ongoing African swine fever epidemic, adversely affecting profits [15]. Other Financial Metrics - Financial expenses decreased by 45.53% to ¥11,891,900.54 mainly due to an increase in exchange gains [25]. - Other income surged by 617.25% to ¥10,808,245.94 primarily from increased government subsidies received [25]. - Investment income dropped by 87.84% to ¥819,362.55 mainly due to the maturity of structured deposits [25]. - Research and development expenses for Q1 2020 amounted to ¥35,621,421.06, compared to ¥32,654,094.66 in Q1 2019, indicating a growth of 9.0% [44]. - The company reported a significant increase in operating expenses due to pandemic-related donations, rising by 1,686,342.81% to ¥3,659,243.61 [25].

Financial Performance - The company's operating revenue for 2019 was approximately CNY 3.73 billion, representing a year-on-year increase of 12.11% compared to CNY 3.33 billion in 2018[25]. - Net profit attributable to shareholders decreased by 24.87% to CNY 121.25 million from CNY 161.39 million in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 63.32 million, down 40.20% from CNY 105.89 million in 2018[25]. - The cash flow from operating activities was CNY 361.87 million, showing a slight increase of 3.07% from CNY 351.09 million in the previous year[25]. - The total assets of the company increased by 7.95% to CNY 7.09 billion from CNY 6.57 billion at the end of 2018[25]. - Basic earnings per share decreased by 26.32% to CNY 0.14 from CNY 0.19 in 2018[25]. - The weighted average return on equity decreased by 1.96 percentage points to 4.08% from 6.04% in the previous year[25]. - The company achieved an annual revenue of 3.733 billion RMB, representing a year-on-year growth of 12.11%[64]. - The net profit attributable to shareholders decreased to 121 million RMB, a decline of 24.87% compared to the previous year[64]. - The operating cash flow net amount increased to 362 million RMB, showing a slight increase of 0.11 million RMB year-on-year[64]. Dividend and Profit Distribution - The board proposed a cash dividend of CNY 0.45 per 10 shares, totaling CNY 39,610,338.08 for 2019, based on a total share capital of 880,229,735 shares[7]. - The company reported a retained profit of RMB 33,278,592.21 to be carried forward to the next fiscal year[183]. - The net profit attributable to ordinary shareholders for 2019 was RMB 121,251,309.89, with a dividend payout ratio of 32.67%[184]. - The company maintained a profit distribution policy that protects the rights of minority investors, with independent directors fulfilling their responsibilities[183]. - The total share capital after the 2019 distribution will be 880,229,735 shares, following the proposed capital increase[183]. - The company has not made any adjustments to its profit distribution policy during the reporting period[184]. Risk Management - There were no significant risks impacting the company's operations during the reporting period[9]. - The company has a comprehensive risk management strategy in place to address potential operational risks[9]. - The company emphasizes that forward-looking statements do not constitute a commitment to investors, highlighting investment risks[8]. - The company has maintained compliance with regulatory decision-making procedures regarding external guarantees[9]. - The company has not engaged in non-operating fund occupation by controlling shareholders or related parties[9]. Research and Development - The company applied for 30 patents during the year, with 23 patents granted, including 3 invention patents and 18 utility model patents[60]. - The company focuses on the development of generic and innovative drugs, particularly in cardiovascular, digestive, and neurodegenerative disease areas[130]. - The company has included 40 products in the 2019 version of the National Medical Insurance Directory, with one product removed[126]. - The company aims to enhance its product structure by diversifying its generic drug offerings and improving existing products[130]. - The company plans to submit clinical applications for three innovative drugs within 1-2 years[128]. - The company's R&D investment for the reporting period was CNY 230.82 million, accounting for 6.18% of operating revenue, which is above the industry average[137]. - The cumulative R&D investment for key projects includes CNY 1,539.57 million for Ticagrelor and CNY 1,673.11 million for Dapagliflozin, both of which have completed registration submissions[140]. - The company has made significant progress in product development, with TRN-157 showing a cumulative R&D investment of CNY 1,002.00 million and currently in preclinical research[142]. Market and Industry Trends - The pharmaceutical industry saw a revenue growth of 9.4% in 2019, with profits increasing by 11.5%[41]. - The pharmaceutical manufacturing industry is undergoing structural adjustments and upgrades, driven by government policies and an aging population[96]. - The company is focusing on high-end specialty raw materials and process improvements to reduce costs in the raw material drug sector[96]. - The "4+7" centralized drug procurement policy has expanded to 25 provinces, indicating a significant shift in the pharmaceutical market dynamics[101]. - The introduction of consistency evaluation for chemical drug injections is expected to accelerate the upgrade of generic drug companies and enhance market competition[105]. - The company aims to strengthen its market share in niche products by leveraging its channel and brand advantages[107]. - The ongoing consistency evaluation for oral solid preparations is progressing, with a focus on risk assessment for new product projects[111]. Production and Sales - The company has a comprehensive product chain in the antibiotic field, covering over 500 specifications including raw materials and formulations[34]. - Revenue from amoxicillin capsules reached 176 million yuan, a year-on-year increase of 20.73%, while cefalexin capsules generated 105 million yuan, up 32.66%[46]. - Sales of penicillin sodium salt and sulbactam sodium increased by 47.37% and 45.3% respectively, while cefazolin sodium and cefazolin acid surged by 145.6% and 379.3%[46]. - The company reported a production volume of 99 million units for Penicillin Sodium, with sales reaching 35 million units[121]. - The production volume for Cefoperazone Sodium for injection was 9,162 million units, with sales of 7,979 million units[121]. - The company produced 196 tons of Cefoperazone Sodium, achieving sales of 90 tons[121]. Financial Management - The company received a standard unqualified audit report from its accounting firm[6]. - The company is committed to ensuring the accuracy and completeness of its financial reports[6]. - The company’s asset-liability ratio rose to 55.26%, an increase of 1.08 percentage points year-on-year[56]. - The company’s cash and cash equivalents decreased significantly, reflecting a strategic shift in financial management[89]. - The company’s investment in construction projects increased by 70.24% to $660,338,804.09, indicating ongoing expansion efforts[89]. Environmental and Regulatory Compliance - The company is committed to enhancing its environmental governance and ensuring compliance with new pollution discharge standards[113]. - The implementation of the new environmental standards for pharmaceutical emissions will require companies to enhance their pollution control measures[112]. - The company faces risks related to industry policy changes, environmental regulations, and the high costs and uncertainties associated with drug research and development[174][176].

2019 年第三季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2019 年第三季度报告 1 / 28 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 28 2019 年第三季度报告 单位：元 币种：人民币 3 / 28 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |------------------------------------------------|------------------------------|-------------------------------- ...